TY-0201R
/ Shenzhen Main Luck Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
August 22, 2025
A phase III clinical study to evaluate the efficacy and safety of TY-0201R in Chinese patients with essential hypertension - a double-blind, parallel-group comparative study with oral bisoprolol fumarate as control-
(ChiCTR)
- P3 | N=430 | Completed | Sponsor: Peking University People's Hospital; Shenzhen Main Luck Pharmaceuticals Inc. | Recruiting ➔ Completed
Trial completion • Cardiovascular • Hypertension
1 to 1
Of
1
Go to page
1